Hsbc Holdings PLC Has $1.11 Million Stock Holdings in Azenta, Inc. $AZTA

Key Points

• Hsbc Holdings PLC increased its Azenta position by 316% in the second quarter, acquiring 33,426 additional shares to hold 44,004 shares worth approximately $1.11 million. Institutional investors and hedge funds collectively own 99.08% of Azenta.
• Azenta reported quarterly EPS of $0.16, exceeding the $0.11 consensus estimate, while revenue of $161.18 million also surpassed expectations of $149.31 million. Despite positive operating results, the company posted a negative net margin of 20.63%.
• Analyst sentiment is mixed: Needham raised its price target to $37 and maintained a Buy rating, while the broader analyst consensus remains Hold, with an average price target of $41.20.

Hsbc Holdings PLC raised its position in Azenta, Inc. (NASDAQ:AZTA - Free Report) by 316.0% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 44,004 shares of the company's stock after acquiring an additional 33,426 shares during the period. Hsbc Holdings PLC owned about 0.10% of Azenta worth $1,108,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd boosted its holdings in Azenta by 2,067.6% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 802 shares of the company's stock worth $27,000 after purchasing an additional 765 shares during the last quarter. State of Wyoming bought a new stake in Azenta during the 1st quarter worth about $38,000. Osaic Holdings Inc. boosted its stake in shares of Azenta by 44.9% during the 2nd quarter. Osaic Holdings Inc. now owns 1,242 shares of the company's stock worth $39,000 after buying an additional 385 shares during the last quarter. Rockefeller Capital Management L.P. boosted its stake in shares of Azenta by 98.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,392 shares of the company's stock worth $46,000 after buying an additional 689 shares during the last quarter. Finally, Allworth Financial LP bought a new position in shares of Azenta in the 2nd quarter valued at about $48,000. Institutional investors and hedge funds own 99.08% of the company's stock.

Azenta Price Performance

Azenta stock opened at $30.85 on Friday. The company's 50-day moving average is $30.22 and its 200-day moving average is $25.33. The firm has a market capitalization of $1.35 billion, a PE ratio of -11.18 and a beta of 1.39. Azenta, Inc. has a fifty-two week low of $15.93 and a fifty-two week high of $41.73.

Azenta (NASDAQ:AZTA - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported $0.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.05. The business had revenue of $161.18 million during the quarter, compared to the consensus estimate of $149.31 million. Azenta had a negative net margin of 20.63% and a positive return on equity of 1.18%.

Analysts Set New Price Targets

Several analysts recently issued reports on AZTA shares. Weiss Ratings upgraded Azenta from a "sell (e+)" rating to a "sell (d-)" rating in a report on Wednesday, August 26th. Needham & Company LLC raised their price target on Azenta from $33.00 to $37.00 and gave the company a "buy" rating in a research note on Wednesday, August 5th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $41.20.

Azenta Company Profile

Azenta, Inc NASDAQ: AZTA is a life sciences company that provides solutions for the management, storage, and analysis of biological samples. Its customers include pharmaceutical and biotechnology companies, academic and government research institutions, clinical research organizations, and other organizations involved in drug discovery, clinical research, and genomic analysis.

The company offers automated sample-management systems, ultra-low-temperature and cryogenic storage equipment, laboratory automation, consumables, and software for tracking and managing biological specimens.

Want to see what other hedge funds are holding AZTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Azenta, Inc. (NASDAQ:AZTA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.